Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Keeps “Buy” Rating at Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reiterated by research analysts at Chardan Capital in a report released on Thursday, Benzinga reports. They presently have a $115.00 price objective on the biotechnology company’s stock. Chardan Capital’s price objective would suggest a potential upside of 97.02% from the company’s current price.

Several other equities analysts have also recently commented on ARWR. Leerink Partners upped their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price target for the company. B. Riley Financial upped their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 30th. The Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a report on Thursday, September 24th. They issued a “neutral” rating and a $74.00 price target for the company. Finally, Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $98.31.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $58.37 on Thursday. Arrowhead Pharmaceuticals has a twelve month low of $36.02 and a twelve month high of $95.49. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. The stock has a market capitalization of $8.22 billion, a PE ratio of -25.94 and a beta of 1.29. The stock has a 50-day simple moving average of $76.71 and a 200 day simple moving average of $75.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The business had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. Arrowhead Pharmaceuticals’s revenue for the quarter was up 171.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.26) EPS. Research analysts anticipate that Arrowhead Pharmaceuticals will post -3.62 EPS for the current year.

Insider Buying and Selling

In related news, Director Michael Perry sold 11,600 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the sale, the director directly owned 111,459 shares in the company, valued at $9,730,370.70. This represents a 9.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adeoye Olukotun sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director owned 31,600 shares in the company, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Versant Capital Management Inc raised its stake in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC raised its stake in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 154 shares during the last quarter. Optiver Holding B.V. raised its stake in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 186 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth about $39,000. Finally, Allied Private Wealth LLC bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth about $43,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: ARO-MAPT produced deep and durable reductions in tau, reaching as much as 73% in healthy volunteers. Arrowhead said the study marks the first successful clinical demonstration of its platform achieving substantial target-gene knockdown in the brain, a potentially important milestone for its central-nervous-system pipeline. Arrowhead ARO-MAPT interim clinical data
• Positive Sentiment: The Alzheimer’s candidate’s ability to cross the blood-brain barrier and reduce tau is driving investor enthusiasm, although the current evidence is limited to an early-stage study in healthy volunteers. Positive ARO-MAPT Phase 1/2a data
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $120 price target, implying substantial upside from the provided $58.37 reference price. The target reflects increased optimism around ARO-MAPT and Arrowhead’s broader CNS pipeline.
• Neutral Sentiment: Management discussed ARO-MAPT’s interim findings and the TRiM CNS delivery platform, highlighting potential pipeline expansion into additional neurological diseases. Arrowhead ARO-MAPT and TRiM discussion
• Negative Sentiment: The data remain preliminary and were generated in healthy volunteers, so they do not yet establish that ARO-MAPT improves cognition or slows Alzheimer’s progression. Further clinical testing and confirmation in patients will be necessary.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.